A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2004-05-18

AUTHORS

Yun Yen, Kim Margolin, James Doroshow, Mayer Fishman, Bonny Johnson, Caroline Clairmont, Dan Sullivan, Mario Sznol

ABSTRACT

Purpose3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumor cell lines. A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer.Study design3-AP and gemcitabine were administered on days 1, 8, and 15 of each 28-day cycle. Initially, 3-AP was infused over 2 h at a fixed dose of 105 mg/m2. Gemcitabine was given over 30 min beginning no less than 1 and no more than 4 h after 3-AP. The first cohort received 3-AP alone in the first cycle. Subsequently, the gemcitabine dose was escalated beginning at 600 mg/m2 in cohorts of three to six patients. Following the gemcitabine 1000 mg/m2 dose level, the study was amended to determine if the 3-AP dose could be escalated above 105 mg/m2.Results3-AP at 105 mg/m2 administered over 2 h followed in 1–4 h by gemcitabine at 1000 mg/m2 produced a toxicity profile similar to that expected for gemcitabine alone at the same dose. When the dose of 3-AP was escalated to 140 and 185 mg/m2 administered over 2 h and subsequently over 4 h, acute hypotension, hypoxia, and EKG changes including non-specific ST-T wave changes and mild QT prolongation were observed, and one patient with underlying diffuse coronary artery disease had an asymptomatic myocardial infarction. 3-AP was shown to cause mild, reversible methemoglobinemia. Average end-of infusion serum concentrations for 3-AP at all doses were within the range capable of enhancing gemcitabine cytotoxicity in vitro. Gemcitabine plasma concentrations at end-of-infusion and elimination half-life were consistent with values reported in the literature. Among 22 evaluable patients, one complete response and two partial responses were observed, and an additional patient had prolonged stabilization of a large liver metastasis.Conclusions3-AP at 105 mg/m2 infused over 2–4 h followed by gemcitabine at 1000 mg/m2 on a days 1, 8, and 15 schedule every 28 days was generally well-tolerated and had a toxicity profile similar to that of gemcitabine alone. 3-AP produced mild to modest methemoglobinemia, which could cause acute symptoms in patients with limited pulmonary or cardiovascular reserve. The combination demonstrated antitumor activity and merits further exploration in phase II trials. More... »

PAGES

331-342

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-004-0821-2

DOI

http://dx.doi.org/10.1007/s00280-004-0821-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1023848029

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15148626


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methemoglobinemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ribonucleotide Reductases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiosemicarbazones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yen", 
        "givenName": "Yun", 
        "id": "sg:person.0760103773.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760103773.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Margolin", 
        "givenName": "Kim", 
        "id": "sg:person.0646721507.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646721507.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "City of Hope Comprehensive Cancer Center, Duarte, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410425.6", 
          "name": [
            "City of Hope Comprehensive Cancer Center, Duarte, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Doroshow", 
        "givenName": "James", 
        "id": "sg:person.01135535666.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135535666.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Moffitt Cancer Center, Tampa, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "Moffitt Cancer Center, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fishman", 
        "givenName": "Mayer", 
        "id": "sg:person.013654276242.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013654276242.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.422300.7", 
          "name": [
            "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Johnson", 
        "givenName": "Bonny", 
        "id": "sg:person.01372110411.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372110411.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.422300.7", 
          "name": [
            "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clairmont", 
        "givenName": "Caroline", 
        "id": "sg:person.01171470045.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171470045.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Moffitt Cancer Center, Tampa, FL, USA", 
          "id": "http://www.grid.ac/institutes/grid.468198.a", 
          "name": [
            "Moffitt Cancer Center, Tampa, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sullivan", 
        "givenName": "Dan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA", 
          "id": "http://www.grid.ac/institutes/grid.422300.7", 
          "name": [
            "Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sznol", 
        "givenName": "Mario", 
        "id": "sg:person.0706626451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-002-0492-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028084925", 
          "https://doi.org/10.1007/s00280-002-0492-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00685844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039603179", 
          "https://doi.org/10.1007/bf00685844"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00686108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009234973", 
          "https://doi.org/10.1007/bf00686108"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01715122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040752626", 
          "https://doi.org/10.1007/bf01715122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1206419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041637695", 
          "https://doi.org/10.1038/sj.onc.1206419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199614060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025177698", 
          "https://doi.org/10.2165/00002018-199614060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199106010-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006454898", 
          "https://doi.org/10.2165/00002018-199106010-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1016214032272", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024266728", 
          "https://doi.org/10.1023/a:1016214032272"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-002-0480-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046014727", 
          "https://doi.org/10.1007/s00280-002-0480-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-05-18", 
    "datePublishedReg": "2004-05-18", 
    "description": "Purpose3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumor cell lines. A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer.Study design3-AP and gemcitabine were administered on days\u00a01, 8, and 15 of each 28-day cycle. Initially, 3-AP was infused over 2\u00a0h at a fixed dose of 105\u00a0mg/m2. Gemcitabine was given over 30\u00a0min beginning no less than 1 and no more than 4\u00a0h after 3-AP. The first cohort received 3-AP alone in the first cycle. Subsequently, the gemcitabine dose was escalated beginning at 600\u00a0mg/m2 in cohorts of three to six patients. Following the gemcitabine 1000\u00a0mg/m2 dose level, the study was amended to determine if the 3-AP dose could be escalated above 105\u00a0mg/m2.Results3-AP at 105\u00a0mg/m2 administered over 2\u00a0h followed in 1\u20134\u00a0h by gemcitabine at 1000\u00a0mg/m2 produced a toxicity profile similar to that expected for gemcitabine alone at the same dose. When the dose of 3-AP was escalated to 140 and 185\u00a0mg/m2 administered over 2\u00a0h and subsequently over 4\u00a0h, acute hypotension, hypoxia, and EKG changes including non-specific ST-T wave changes and mild QT prolongation were observed, and one patient with underlying diffuse coronary artery disease had an asymptomatic myocardial infarction. 3-AP was shown to cause mild, reversible methemoglobinemia. Average end-of infusion serum concentrations for 3-AP at all doses were within the range capable of enhancing gemcitabine cytotoxicity in vitro. Gemcitabine plasma concentrations at end-of-infusion and elimination half-life were consistent with values reported in the literature. Among 22 evaluable patients, one complete response and two partial responses were observed, and an additional patient had prolonged stabilization of a large liver metastasis.Conclusions3-AP at 105\u00a0mg/m2 infused over 2\u20134\u00a0h followed by gemcitabine at 1000\u00a0mg/m2 on a days\u00a01, 8, and 15 schedule every 28\u00a0days was generally well-tolerated and had a toxicity profile similar to that of gemcitabine alone. 3-AP produced mild to modest methemoglobinemia, which could cause acute symptoms in patients with limited pulmonary or cardiovascular reserve. The combination demonstrated antitumor activity and merits further exploration in phase II trials.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-004-0821-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "54"
      }
    ], 
    "keywords": [
      "phase I trial", 
      "I trial", 
      "advanced cancer", 
      "toxicity profile", 
      "diffuse coronary artery disease", 
      "ST-T wave changes", 
      "non-specific ST-T wave changes", 
      "Gemcitabine plasma concentrations", 
      "large liver metastases", 
      "phase II trial", 
      "coronary artery disease", 
      "asymptomatic myocardial infarction", 
      "mild QT prolongation", 
      "cytotoxicity of gemcitabine", 
      "gemcitabine dose", 
      "gemcitabine 1000", 
      "evaluable patients", 
      "acute hypotension", 
      "partial response", 
      "II trial", 
      "artery disease", 
      "complete response", 
      "liver metastases", 
      "cardiovascular reserve", 
      "additional patients", 
      "acute symptoms", 
      "safety profile", 
      "QT prolongation", 
      "myocardial infarction", 
      "serum concentrations", 
      "plasma concentrations", 
      "same dose", 
      "gemcitabine", 
      "patients", 
      "dose levels", 
      "gemcitabine cytotoxicity", 
      "tumor cell lines", 
      "dose", 
      "antitumor activity", 
      "first cohort", 
      "trials", 
      "wave changes", 
      "cell lines", 
      "DNA incorporation", 
      "cohort", 
      "cancer", 
      "methemoglobinemia", 
      "doses", 
      "potent inhibitor", 
      "days", 
      "cytotoxicity", 
      "cellular uptake", 
      "further exploration", 
      "hypotension", 
      "infarction", 
      "ribonucleotide reductase", 
      "metastasis", 
      "infusion", 
      "symptoms", 
      "EKG", 
      "disease", 
      "prolongation", 
      "hypoxia", 
      "carboxaldehyde thiosemicarbazones", 
      "response", 
      "first cycle", 
      "m2", 
      "inhibitors", 
      "profile", 
      "combination", 
      "concentration", 
      "min", 
      "uptake", 
      "levels", 
      "schedule", 
      "activity", 
      "elimination", 
      "study", 
      "end", 
      "changes", 
      "reductase", 
      "cycle", 
      "literature", 
      "lines", 
      "reserves", 
      "stabilization", 
      "incorporation", 
      "values", 
      "exploration", 
      "thiosemicarbazone", 
      "range", 
      "average end"
    ], 
    "name": "A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer", 
    "pagination": "331-342", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1023848029"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-004-0821-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15148626"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-004-0821-2", 
      "https://app.dimensions.ai/details/publication/pub.1023848029"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_393.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-004-0821-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0821-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0821-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0821-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-004-0821-2'


 

This table displays all metadata directly associated to this object as RDF triples.

299 TRIPLES      21 PREDICATES      140 URIs      123 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-004-0821-2 schema:about N0b68882a804c4ff9bcffadea7e8efaf1
2 N23d442d679144ba5ba86778600f3e827
3 N27a0566b831f482c845552f763a8c0bb
4 N70ec07a1b9a94e31ac4143720611a3b1
5 N72fd48be10a54cff9e084a19a4a5405f
6 N926477f9f8ac49b5b9a8b39f9fc999c3
7 N972054f54f5848ac82b7d6bd5f51eeb7
8 N9fdabc0655c2453e9ec24f9225a1aaa2
9 Nad754280013c4c94aa0a1988ec6d1234
10 Nb457534057da454fa740379f0168b276
11 Nc4d43592c6a84b14ba83dacaef52aa3d
12 Nf05507dc3b3f499590cab02ca1f49726
13 Nf76885ca0e90489186ecad885f0b7e05
14 Nfb4cea886f0b435eb30185a478047ca7
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N855341e3977c424ba17985bdae760ea4
18 schema:citation sg:pub.10.1007/bf00685844
19 sg:pub.10.1007/bf00686108
20 sg:pub.10.1007/bf01715122
21 sg:pub.10.1007/s00280-002-0480-0
22 sg:pub.10.1007/s00280-002-0492-9
23 sg:pub.10.1023/a:1016214032272
24 sg:pub.10.1038/sj.onc.1206419
25 sg:pub.10.2165/00002018-199106010-00004
26 sg:pub.10.2165/00002018-199614060-00005
27 schema:datePublished 2004-05-18
28 schema:datePublishedReg 2004-05-18
29 schema:description Purpose3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a new and potent inhibitor of ribonucleotide reductase (RR), increases the cellular uptake, DNA incorporation, and cytotoxicity of gemcitabine in tumor cell lines. A phase I trial was initiated to determine the safety profile and maximum tolerated doses of 3-AP and gemcitabine when used in combination in patients with advanced cancer.Study design3-AP and gemcitabine were administered on days 1, 8, and 15 of each 28-day cycle. Initially, 3-AP was infused over 2 h at a fixed dose of 105 mg/m2. Gemcitabine was given over 30 min beginning no less than 1 and no more than 4 h after 3-AP. The first cohort received 3-AP alone in the first cycle. Subsequently, the gemcitabine dose was escalated beginning at 600 mg/m2 in cohorts of three to six patients. Following the gemcitabine 1000 mg/m2 dose level, the study was amended to determine if the 3-AP dose could be escalated above 105 mg/m2.Results3-AP at 105 mg/m2 administered over 2 h followed in 1–4 h by gemcitabine at 1000 mg/m2 produced a toxicity profile similar to that expected for gemcitabine alone at the same dose. When the dose of 3-AP was escalated to 140 and 185 mg/m2 administered over 2 h and subsequently over 4 h, acute hypotension, hypoxia, and EKG changes including non-specific ST-T wave changes and mild QT prolongation were observed, and one patient with underlying diffuse coronary artery disease had an asymptomatic myocardial infarction. 3-AP was shown to cause mild, reversible methemoglobinemia. Average end-of infusion serum concentrations for 3-AP at all doses were within the range capable of enhancing gemcitabine cytotoxicity in vitro. Gemcitabine plasma concentrations at end-of-infusion and elimination half-life were consistent with values reported in the literature. Among 22 evaluable patients, one complete response and two partial responses were observed, and an additional patient had prolonged stabilization of a large liver metastasis.Conclusions3-AP at 105 mg/m2 infused over 2–4 h followed by gemcitabine at 1000 mg/m2 on a days 1, 8, and 15 schedule every 28 days was generally well-tolerated and had a toxicity profile similar to that of gemcitabine alone. 3-AP produced mild to modest methemoglobinemia, which could cause acute symptoms in patients with limited pulmonary or cardiovascular reserve. The combination demonstrated antitumor activity and merits further exploration in phase II trials.
30 schema:genre article
31 schema:isAccessibleForFree false
32 schema:isPartOf N162001c73d4e49eb8c321915378c1768
33 Nfda0751d974a480ab0974b1ef3900828
34 sg:journal.1088364
35 schema:keywords DNA incorporation
36 EKG
37 Gemcitabine plasma concentrations
38 I trial
39 II trial
40 QT prolongation
41 ST-T wave changes
42 activity
43 acute hypotension
44 acute symptoms
45 additional patients
46 advanced cancer
47 antitumor activity
48 artery disease
49 asymptomatic myocardial infarction
50 average end
51 cancer
52 carboxaldehyde thiosemicarbazones
53 cardiovascular reserve
54 cell lines
55 cellular uptake
56 changes
57 cohort
58 combination
59 complete response
60 concentration
61 coronary artery disease
62 cycle
63 cytotoxicity
64 cytotoxicity of gemcitabine
65 days
66 diffuse coronary artery disease
67 disease
68 dose
69 dose levels
70 doses
71 elimination
72 end
73 evaluable patients
74 exploration
75 first cohort
76 first cycle
77 further exploration
78 gemcitabine
79 gemcitabine 1000
80 gemcitabine cytotoxicity
81 gemcitabine dose
82 hypotension
83 hypoxia
84 incorporation
85 infarction
86 infusion
87 inhibitors
88 large liver metastases
89 levels
90 lines
91 literature
92 liver metastases
93 m2
94 metastasis
95 methemoglobinemia
96 mild QT prolongation
97 min
98 myocardial infarction
99 non-specific ST-T wave changes
100 partial response
101 patients
102 phase I trial
103 phase II trial
104 plasma concentrations
105 potent inhibitor
106 profile
107 prolongation
108 range
109 reductase
110 reserves
111 response
112 ribonucleotide reductase
113 safety profile
114 same dose
115 schedule
116 serum concentrations
117 stabilization
118 study
119 symptoms
120 thiosemicarbazone
121 toxicity profile
122 trials
123 tumor cell lines
124 uptake
125 values
126 wave changes
127 schema:name A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer
128 schema:pagination 331-342
129 schema:productId N28cc7fad81334727a14c07bc842f1742
130 Nbf9fbe470e3546008e31d912cf443825
131 Nd5922dd52fb0446bac7f4567b3d47f71
132 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023848029
133 https://doi.org/10.1007/s00280-004-0821-2
134 schema:sdDatePublished 2022-09-02T15:50
135 schema:sdLicense https://scigraph.springernature.com/explorer/license/
136 schema:sdPublisher Nf8fac0904e0a4c0d8b706967708fc63e
137 schema:url https://doi.org/10.1007/s00280-004-0821-2
138 sgo:license sg:explorer/license/
139 sgo:sdDataset articles
140 rdf:type schema:ScholarlyArticle
141 N07f07ed2a3a44d3bab15909358fc8b57 rdf:first sg:person.0646721507.30
142 rdf:rest Na3d51ae4fa654560a5f824b95f341d92
143 N0b68882a804c4ff9bcffadea7e8efaf1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged
145 rdf:type schema:DefinedTerm
146 N162001c73d4e49eb8c321915378c1768 schema:volumeNumber 54
147 rdf:type schema:PublicationVolume
148 N23d442d679144ba5ba86778600f3e827 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Thiosemicarbazones
150 rdf:type schema:DefinedTerm
151 N27a0566b831f482c845552f763a8c0bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Neoplasms
153 rdf:type schema:DefinedTerm
154 N28cc7fad81334727a14c07bc842f1742 schema:name dimensions_id
155 schema:value pub.1023848029
156 rdf:type schema:PropertyValue
157 N3a8ed78be57d45b2b850cd1b12d73d9e rdf:first sg:person.01372110411.35
158 rdf:rest N9c2be6108b01414e892732a32a02a445
159 N5cda5a68a6f54c6eaa6a021023ee6437 rdf:first sg:person.013654276242.49
160 rdf:rest N3a8ed78be57d45b2b850cd1b12d73d9e
161 N70ec07a1b9a94e31ac4143720611a3b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Middle Aged
163 rdf:type schema:DefinedTerm
164 N72fd48be10a54cff9e084a19a4a5405f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Pyridines
166 rdf:type schema:DefinedTerm
167 N855341e3977c424ba17985bdae760ea4 rdf:first sg:person.0760103773.19
168 rdf:rest N07f07ed2a3a44d3bab15909358fc8b57
169 N926477f9f8ac49b5b9a8b39f9fc999c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Deoxycytidine
171 rdf:type schema:DefinedTerm
172 N972054f54f5848ac82b7d6bd5f51eeb7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Male
174 rdf:type schema:DefinedTerm
175 N9c2be6108b01414e892732a32a02a445 rdf:first sg:person.01171470045.80
176 rdf:rest Nc063cc1246664e0d9e4e42c9435df690
177 N9fdabc0655c2453e9ec24f9225a1aaa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Drug Administration Schedule
179 rdf:type schema:DefinedTerm
180 Na3d51ae4fa654560a5f824b95f341d92 rdf:first sg:person.01135535666.03
181 rdf:rest N5cda5a68a6f54c6eaa6a021023ee6437
182 Nad754280013c4c94aa0a1988ec6d1234 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Adult
184 rdf:type schema:DefinedTerm
185 Nb457534057da454fa740379f0168b276 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Methemoglobinemia
187 rdf:type schema:DefinedTerm
188 Nbf9fbe470e3546008e31d912cf443825 schema:name doi
189 schema:value 10.1007/s00280-004-0821-2
190 rdf:type schema:PropertyValue
191 Nc063cc1246664e0d9e4e42c9435df690 rdf:first Nd7b7fead1df34d47b06a73493fd714fd
192 rdf:rest Nf917ce86dea1405b98c4c24aa0a7e4a8
193 Nc4d43592c6a84b14ba83dacaef52aa3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Ribonucleotide Reductases
195 rdf:type schema:DefinedTerm
196 Nd5922dd52fb0446bac7f4567b3d47f71 schema:name pubmed_id
197 schema:value 15148626
198 rdf:type schema:PropertyValue
199 Nd7b7fead1df34d47b06a73493fd714fd schema:affiliation grid-institutes:grid.468198.a
200 schema:familyName Sullivan
201 schema:givenName Dan
202 rdf:type schema:Person
203 Nf05507dc3b3f499590cab02ca1f49726 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Female
205 rdf:type schema:DefinedTerm
206 Nf76885ca0e90489186ecad885f0b7e05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Humans
208 rdf:type schema:DefinedTerm
209 Nf8fac0904e0a4c0d8b706967708fc63e schema:name Springer Nature - SN SciGraph project
210 rdf:type schema:Organization
211 Nf917ce86dea1405b98c4c24aa0a7e4a8 rdf:first sg:person.0706626451.72
212 rdf:rest rdf:nil
213 Nfb4cea886f0b435eb30185a478047ca7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Antineoplastic Combined Chemotherapy Protocols
215 rdf:type schema:DefinedTerm
216 Nfda0751d974a480ab0974b1ef3900828 schema:issueNumber 4
217 rdf:type schema:PublicationIssue
218 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
219 schema:name Medical and Health Sciences
220 rdf:type schema:DefinedTerm
221 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
222 schema:name Oncology and Carcinogenesis
223 rdf:type schema:DefinedTerm
224 sg:journal.1088364 schema:issn 0344-5704
225 1432-0843
226 schema:name Cancer Chemotherapy and Pharmacology
227 schema:publisher Springer Nature
228 rdf:type schema:Periodical
229 sg:person.01135535666.03 schema:affiliation grid-institutes:grid.410425.6
230 schema:familyName Doroshow
231 schema:givenName James
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135535666.03
233 rdf:type schema:Person
234 sg:person.01171470045.80 schema:affiliation grid-institutes:grid.422300.7
235 schema:familyName Clairmont
236 schema:givenName Caroline
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171470045.80
238 rdf:type schema:Person
239 sg:person.013654276242.49 schema:affiliation grid-institutes:grid.468198.a
240 schema:familyName Fishman
241 schema:givenName Mayer
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013654276242.49
243 rdf:type schema:Person
244 sg:person.01372110411.35 schema:affiliation grid-institutes:grid.422300.7
245 schema:familyName Johnson
246 schema:givenName Bonny
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372110411.35
248 rdf:type schema:Person
249 sg:person.0646721507.30 schema:affiliation grid-institutes:grid.410425.6
250 schema:familyName Margolin
251 schema:givenName Kim
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646721507.30
253 rdf:type schema:Person
254 sg:person.0706626451.72 schema:affiliation grid-institutes:grid.422300.7
255 schema:familyName Sznol
256 schema:givenName Mario
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0706626451.72
258 rdf:type schema:Person
259 sg:person.0760103773.19 schema:affiliation grid-institutes:grid.410425.6
260 schema:familyName Yen
261 schema:givenName Yun
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760103773.19
263 rdf:type schema:Person
264 sg:pub.10.1007/bf00685844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039603179
265 https://doi.org/10.1007/bf00685844
266 rdf:type schema:CreativeWork
267 sg:pub.10.1007/bf00686108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009234973
268 https://doi.org/10.1007/bf00686108
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/bf01715122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040752626
271 https://doi.org/10.1007/bf01715122
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s00280-002-0480-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046014727
274 https://doi.org/10.1007/s00280-002-0480-0
275 rdf:type schema:CreativeWork
276 sg:pub.10.1007/s00280-002-0492-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028084925
277 https://doi.org/10.1007/s00280-002-0492-9
278 rdf:type schema:CreativeWork
279 sg:pub.10.1023/a:1016214032272 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024266728
280 https://doi.org/10.1023/a:1016214032272
281 rdf:type schema:CreativeWork
282 sg:pub.10.1038/sj.onc.1206419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041637695
283 https://doi.org/10.1038/sj.onc.1206419
284 rdf:type schema:CreativeWork
285 sg:pub.10.2165/00002018-199106010-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006454898
286 https://doi.org/10.2165/00002018-199106010-00004
287 rdf:type schema:CreativeWork
288 sg:pub.10.2165/00002018-199614060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025177698
289 https://doi.org/10.2165/00002018-199614060-00005
290 rdf:type schema:CreativeWork
291 grid-institutes:grid.410425.6 schema:alternateName City of Hope Comprehensive Cancer Center, Duarte, CA, USA
292 schema:name City of Hope Comprehensive Cancer Center, Duarte, CA, USA
293 rdf:type schema:Organization
294 grid-institutes:grid.422300.7 schema:alternateName Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA
295 schema:name Vion Pharmaceuticals, Inc., 4 Science Park, CT 06511, New Haven, USA
296 rdf:type schema:Organization
297 grid-institutes:grid.468198.a schema:alternateName Moffitt Cancer Center, Tampa, FL, USA
298 schema:name Moffitt Cancer Center, Tampa, FL, USA
299 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...